Ustekinumab May Be Effective for Lupus

Between Week 0 and 24, 78% of patients in the ustekinumab group and 67% of patients in the placebo group had at least one adverse event. Approximately half the patients in each group experienced the most common type of adverse event, which was infection. No deaths, treatment-emergent opportunistic infections, herpes zoster, tuberculosis or malignancies were reported during the study period.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

Reference

van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: Results of a multicentre, double-blind, phase 2, randomized, controlled study. Lancet. 2018 Oct 13;392(10155):1330–1339.

A new biologic agent for treatment of systemic lupus erythematosus (SLE) being tested in clinical trials is showing promise as a safe and effective new treatment, particularly in patients with more severe disease or serologically active disease. Recently published results of a study that examined the safety and efficacy of atacicept for SLE showed the…

After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.

Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

Progress toward targeted therapy

Atacicept Shows Promise in Lupus Treatment Trials

FDA Approves Ustekinumab for Children with PsA

Top 12: Research in Systemic Lupus Erythematosus at a Glance

T Cells in Systemic Lupus Erythematosus

Related Articles